Aaron U Blackham1, Erin Greenleaf2, Maki Yamamoto1, Chris Hollenbeak2, Niraj Gusani2, Domenico Coppola3,4,5, Jose M Pimiento1,4, Joyce Wong2. 1. Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida. 2. Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania. 3. Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida. 4. Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida. 5. Department of Chemical Biology and Molecular Medicine, Moffitt Cancer Center, Tampa, Florida.
Abstract
BACKGROUND: The clinical value and prognostic implications of histologic response to neoadjuvant chemotherapy in gastric cancer is unknown. METHODS: Tumor regression grade (TRG) was recorded in 58 gastric cancer patients identified from two institutional surgical databases. TRG 1a/b represented histologic responders (<10% viable tumor), while TRG 2/3 represented non-responders (>10% viable tumor). RESULTS: TRG 1a/b was recorded in 10 patients (17%), while 48 patients (83%) had a TRG 2/3 response. Larger tumor size (OR 0.24; 95%CI 0.09, 0.64; P = 0.004) and clinical downstaging (OR 30.0; 95%CI 3.26, 276; P = 0.003) were the only factors predictive of histologic response. TRG 1a/b responders had 3-year survival of 70.0% and an estimated overall survival of >69.8 months compared to 38.2% and 22.8 months in non-responders; however, this trend was not statistically significant (P = 0.535). While TRG could not predict survival (OR 2.40; 95%CI 0.46, 12.57; P = 0.300), patient age (OR 1.06; 95%CI 1.00, 1.11; P = 0.035), and the number of positive lymph nodes (≥7; OR 0.05; 95%CI 0.07, 0.27; P < 0.001) were independent predictors of survival. CONCLUSIONS: Few gastric cancers demonstrate histologic response to neoadjuvant chemotherapy. While TRG may be a valid marker for treatment response, its predictive value and clinical application in gastric cancer remains unclear. J. Surg. Oncol. 2016;114:434-439.
BACKGROUND: The clinical value and prognostic implications of histologic response to neoadjuvant chemotherapy in gastric cancer is unknown. METHODS:Tumor regression grade (TRG) was recorded in 58 gastric cancerpatients identified from two institutional surgical databases. TRG 1a/b represented histologic responders (<10% viable tumor), while TRG 2/3 represented non-responders (>10% viable tumor). RESULTS: TRG 1a/b was recorded in 10 patients (17%), while 48 patients (83%) had a TRG 2/3 response. Larger tumor size (OR 0.24; 95%CI 0.09, 0.64; P = 0.004) and clinical downstaging (OR 30.0; 95%CI 3.26, 276; P = 0.003) were the only factors predictive of histologic response. TRG 1a/b responders had 3-year survival of 70.0% and an estimated overall survival of >69.8 months compared to 38.2% and 22.8 months in non-responders; however, this trend was not statistically significant (P = 0.535). While TRG could not predict survival (OR 2.40; 95%CI 0.46, 12.57; P = 0.300), patient age (OR 1.06; 95%CI 1.00, 1.11; P = 0.035), and the number of positive lymph nodes (≥7; OR 0.05; 95%CI 0.07, 0.27; P < 0.001) were independent predictors of survival. CONCLUSIONS: Few gastric cancers demonstrate histologic response to neoadjuvant chemotherapy. While TRG may be a valid marker for treatment response, its predictive value and clinical application in gastric cancer remains unclear. J. Surg. Oncol. 2016;114:434-439.
Authors: Yanshuo Cao; Qing Chang; Michael Cabanero; Wenjiang Zhang; Sara Hafezi-Bakhtiari; David Hedley; Gail Darling; Fayez Quereshy; Raymond Jang; Elena Elimova; Jennifer Knox; Olga Ornatsky; Stefano Serra; Eric Chen Journal: J Gastrointest Cancer Date: 2019-12
Authors: Naruhiko Ikoma; Mariela Blum; Jeannelyn S Estrella; Prajnan Das; Wayne L Hofstetter; Keith F Fournier; Paul Mansfield; Jaffer A Ajani; Brian D Badgwell Journal: Gastric Cancer Date: 2017-06-22 Impact factor: 7.370
Authors: Naruhiko Ikoma; Jeannelyn S Estrella; Mariela Blum Murphy; Prajnan Das; Bruce D Minsky; Paul Mansfield; Jaffer A Ajani; Brian D Badgwell Journal: J Gastrointest Surg Date: 2020-06-15 Impact factor: 3.452
Authors: Pietro Achilli; Paolo De Martini; Marco Ceresoli; Giulio M Mari; Andrea Costanzi; Dario Maggioni; Raffaele Pugliese; Giovanni Ferrari Journal: J Gastrointest Oncol Date: 2017-12